154 related articles for article (PubMed ID: 16762541)
1. Analysis of aneusomy level and HER-2 gene copy number and their effect on amplification rate in breast cancer specimens read as 2+ in immunohistochemical analysis.
Merola R; Mottolese M; Orlandi G; Vico E; Cognetti F; Sperduti I; Fabi A; Vitelli G; Cianciulli AM
Eur J Cancer; 2006 Jul; 42(10):1501-6. PubMed ID: 16762541
[TBL] [Abstract][Full Text] [Related]
2. Aneusomy 17 in breast cancer: its role in HER-2/neu protein expression and implication for clinical assessment of HER-2/neu status.
Wang S; Hossein Saboorian M; Frenkel EP; Haley BB; Siddiqui MT; Gokaslan S; Hynan L; Ashfaq R
Mod Pathol; 2002 Feb; 15(2):137-45. PubMed ID: 11850542
[TBL] [Abstract][Full Text] [Related]
3. Polysomy 17 in HER-2/neu status elaboration in breast cancer: effect on daily practice.
Ma Y; Lespagnard L; Durbecq V; Paesmans M; Desmedt C; Gomez-Galdon M; Veys I; Cardoso F; Sotiriou C; Di Leo A; Piccart MJ; Larsimont D
Clin Cancer Res; 2005 Jun; 11(12):4393-9. PubMed ID: 15958623
[TBL] [Abstract][Full Text] [Related]
4. Polysomy of chromosome 17 in breast cancer tumors showing an overexpression of ERBB2: a study of 175 cases using fluorescence in situ hybridization and immunohistochemistry.
Salido M; Tusquets I; Corominas JM; Suarez M; Espinet B; Corzo C; Bellet M; Fabregat X; Serrano S; Solé F
Breast Cancer Res; 2005; 7(2):R267-73. PubMed ID: 15743507
[TBL] [Abstract][Full Text] [Related]
5. The effect of chromosome 17 polysomy on HER-2/neu status in breast cancer.
Hyun CL; Lee HE; Kim KS; Kim SW; Kim JH; Choe G; Park SY
J Clin Pathol; 2008 Mar; 61(3):317-21. PubMed ID: 17761736
[TBL] [Abstract][Full Text] [Related]
6. Impact of polysomy 17 on HER-2/neu immunohistochemistry in breast carcinomas without HER-2/neu gene amplification.
Lal P; Salazar PA; Ladanyi M; Chen B
J Mol Diagn; 2003 Aug; 5(3):155-9. PubMed ID: 12876205
[TBL] [Abstract][Full Text] [Related]
7. HER-2 gene amplification by fluorescence in situ hybridization (FISH) compared with immunohistochemistry (IHC) in breast cancer: a study of 528 equivocal cases.
Zhang H; Ren G; Wang X; Zhao J; Yao H; Bai Y; Bo W
Breast Cancer Res Treat; 2012 Jul; 134(2):743-9. PubMed ID: 22678158
[TBL] [Abstract][Full Text] [Related]
8. Real-time reverse transcription-PCR and fluorescence in-situ hybridization are complementary to understand the mechanisms involved in HER-2/neu overexpression in human breast carcinomas.
Vanden Bempt I; Vanhentenrijk V; Drijkoningen M; Wlodarska I; Vandenberghe P; De Wolf-Peeters C
Histopathology; 2005 Apr; 46(4):431-41. PubMed ID: 15810955
[TBL] [Abstract][Full Text] [Related]
9. AQUA and FISH analysis of HER-2/neu expression and amplification in a small cell lung carcinoma tissue microarray.
Giltnane JM; Murren JR; Rimm DL; King BL
Histopathology; 2006 Aug; 49(2):161-9. PubMed ID: 16879393
[TBL] [Abstract][Full Text] [Related]
10. Role of polysomy 17 in transitional cell carcinoma of the bladder: immunohistochemical study of HER2/neu expression and fish analysis of c-erbB-2 gene and chromosome 17.
Simonetti S; Russo R; Ciancia G; Altieri V; De Rosa G; Insabato L
Int J Surg Pathol; 2009 Jun; 17(3):198-205. PubMed ID: 19443884
[TBL] [Abstract][Full Text] [Related]
11. HER-2 amplification in tubular carcinoma of the breast.
Oakley GJ; Tubbs RR; Crowe J; Sebek B; Budd GT; Patrick RJ; Procop GW
Am J Clin Pathol; 2006 Jul; 126(1):55-8. PubMed ID: 16753605
[TBL] [Abstract][Full Text] [Related]
12. HER-2 gene amplification, HER-2 and epidermal growth factor receptor mRNA and protein expression, and lapatinib efficacy in women with metastatic breast cancer.
Press MF; Finn RS; Cameron D; Di Leo A; Geyer CE; Villalobos IE; Santiago A; Guzman R; Gasparyan A; Ma Y; Danenberg K; Martin AM; Williams L; Oliva C; Stein S; Gagnon R; Arbushites M; Koehler MT
Clin Cancer Res; 2008 Dec; 14(23):7861-70. PubMed ID: 19047115
[TBL] [Abstract][Full Text] [Related]
13. Absence of chromosome 17 polysomy in breast cancer: analysis by CEP17 chromogenic in situ hybridization and multiplex ligation-dependent probe amplification.
Moelans CB; de Weger RA; van Diest PJ
Breast Cancer Res Treat; 2010 Feb; 120(1):1-7. PubMed ID: 19760503
[TBL] [Abstract][Full Text] [Related]
14. Chromogenic in situ hybridization for the detection of HER-2/neu gene amplification in breast cancer with an emphasis on tumors with borderline and low-level amplification: does it measure up to fluorescence in situ hybridization?
Bhargava R; Lal P; Chen B
Am J Clin Pathol; 2005 Feb; 123(2):237-43. PubMed ID: 15842048
[TBL] [Abstract][Full Text] [Related]
15. Analysis of ERBB2 and TOP2A gene status using fluorescence in situ hybridization versus immunohistochemistry in localized breast cancer.
Bouchalová K; Trojanec R; Kolár Z; Cwiertka K; Cernáková I; Mihál V; Hajdúch M
Neoplasma; 2006; 53(5):393-401. PubMed ID: 17013533
[TBL] [Abstract][Full Text] [Related]
16. Detection of Her-2/neu oncogene in breast carcinoma by chromogenic in situ hybridization in cytologic specimens.
Lin F; Shen T; Prichard JW
Diagn Cytopathol; 2005 Dec; 33(6):376-80. PubMed ID: 16299744
[TBL] [Abstract][Full Text] [Related]
17. ERBB-2 (HER2/neu) gene copy number, p185HER-2 overexpression, and intratumor heterogeneity in human breast cancer.
Szöllösi J; Balázs M; Feuerstein BG; Benz CC; Waldman FM
Cancer Res; 1995 Nov; 55(22):5400-7. PubMed ID: 7585609
[TBL] [Abstract][Full Text] [Related]
18. HER-2 testing in breast cancer using immunohistochemical analysis and fluorescence in situ hybridization: a single-institution experience of 2,279 cases and comparison of dual-color and single-color scoring.
Lal P; Salazar PA; Hudis CA; Ladanyi M; Chen B
Am J Clin Pathol; 2004 May; 121(5):631-6. PubMed ID: 15151202
[TBL] [Abstract][Full Text] [Related]
19. Determination of HER-2 status and chromosome 17 polysomy in breast carcinomas comparing HercepTest and PathVysion FISH assay.
Varshney D; Zhou YY; Geller SA; Alsabeh R
Am J Clin Pathol; 2004 Jan; 121(1):70-7. PubMed ID: 14750243
[TBL] [Abstract][Full Text] [Related]
20. HER-2/neu oncogene amplification and chromosome 17 aneusomy in endometrial carcinoma: correlation with oncoprotein expression and conventional pathological parameters.
Cianciulli AM; Guadagni F; Marzano R; Benevolo M; Merola R; Giannarelli D; Marandino F; Vocaturo G; Mariani L; Mottolese M
J Exp Clin Cancer Res; 2003 Jun; 22(2):265-71. PubMed ID: 12866577
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
